Shionogi Expects Crestor To Overtake Pfizer’s Lipitor
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi & Co. of Osaka is projecting domestic sales of its cholesterol treatment Crestor (rosuvastatin) to grow 82 percent in fiscal 2008 to ¥19 billion ($180 million), thanks to its lower price and additional efficacy compared to competitor Pfizer's Lipitor (atorvastatin), a company official said July 2